reMYND NV

ARCH Venture Partners raised its largest venture capital fund yet, the $1.85bn ARCH Venture Fund XI, which it plans to invest in a range of biotechnology opportunities, including drug developers focus

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in

Roche has licensed two preclinical programmes focused on therapeutics to slow down neurodegenerative disorders from reMYND, a small Belgian biotechnology company. The deal that could be worth more tha

In Vitro Diagnostics Acquisitions /In Vitro Diagnostics Abbott Laboratories Inc. Celera Corp. In a four-year deal, Celera Corp. has licensed Abbott Laboratories Inc. exclusive rights to distri